Search Results
May 31, 2026, 20:00 ET Carbice and Noctua Partner to Bring Advanced Thermal Pad Technology to DIY PC Builders
the same vertically aligned carbon nanotube technology Carbice supplies for satellites, aerospace systems, and AI infrastructure, in a peel-and-stick form factor sized for consumer CPUs.The Carbice® IP90 thermal pad is currently available pre-applied in gaming desktop PCs from CyberPowerPC,
More news about: Carbice Corporation
May 31, 2026, 20:00 ET D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC
(D3S-001)Elisrasib is a next-generation KRAS G12C inhibitor designed for rapid, complete, and selective target engagement. It covalently binds the GDP-bound (OFF) form of KRAS G12C, effectively blocking nucleotide cycling and suppressing oncogenic signaling. Preclinical studies show robust potency, complete KRAS G12C
More news about: D3 Bio
May 31, 2026, 18:00 ET Cango Inc. Reports First Quarter 2026 Unaudited Financial Results
forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC") , in its annual report on Form 20-F, its current reports on Form 6-K, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties.
More news about: Cango Inc.
May 31, 2026, 16:30 ET Berkshire Hathaway to Acquire Taylor Morrison Home Corporation for $8.5 Billion
annual meeting of stockholders, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the participants in the proxy solicitation and a description of their
More news about: Taylor Morrison Home Corporation
May 31, 2026, 09:00 ET HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated
More news about: Akeso, Inc.
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange
More news about: Johnson & Johnson
May 31, 2026, 08:27 ET Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange
More news about: Johnson & Johnson
May 31, 2026, 08:01 ET Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking
More news about: Eli Lilly and Company
May 31, 2026, 08:00 ET GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
forward-looking statements, including those factors and numerous associated risks discussed under the section entitled "Risk Factors" in our Annual Report on Form 10-K for the period ended December 31, 2025. Moreover, we operate in a dynamic and rapidly changing environment. New risks emerge from time to time.
More news about: GRAIL, Inc.
May 30, 2026, 18:36 ET STLA Deadline: STLA Investors with Losses in Excess of $100K Have Opportunity to Lead Stellantis N.V. Securities Fraud Lawsuit
https://rosenlegal.com/submit-form/?case_id=27632 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected]
More news about: THE ROSEN LAW FIRM, P. A.
May 30, 2026, 17:31 ET SES AI Corporation Deadline: SES Investors with Losses in Excess of $100K Have Opportunity to Lead SES AI Corporation Securities Fraud Lawsuit Filed by The Rosen Law Firm
https://rosenlegal.com/submit-form/?case_id=56471 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected]
More news about: THE ROSEN LAW FIRM, P. A.
May 30, 2026, 17:07 ET NUAI Deadline: NUAI Investors with Losses in Excess of $100K Have Opportunity to Lead New Era Energy & Digital, Inc. Securities Fraud Lawsuit
https://rosenlegal.com/submit-form/?case_id=49293 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected]
More news about: THE ROSEN LAW FIRM, P. A.
May 30, 2026, 14:30 ET Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, including under the caption "Item 1A. Risk Factors," and in Whitehawk's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Whitehawk's reports and other documents that Whitehawk
More news about: Whitehawk Therapeutics, Inc.
May 30, 2026, 14:30 ET Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.Investor Contact:Steven M. HarasymTel:
More news about: Precigen, Inc.
May 30, 2026, 10:34 ET Gravity Game Unite (GGU) schließt die offene Beta-Phase für das PC-MMORPG Ragnarok Zero: Global erfolgreich ab
Serverstabilität und der Optimierung.Ragnarok Zero: Global lässt den klassischen Charme des Originals Ragnarok Online in moderner Form wiederaufleben und hebt sich gleichzeitig durch eine neue, aus dem bestehenden Universum erweiterte Handlung sowie durch Änderungen an der Entwicklungsstruktur
More news about: Gravity Game Unite SDN. BHD.
May 30, 2026, 08:00 ET The Rosen Law Firm, P.A. Continues to Remind Investors of the Proposed Class Action Settlement on Behalf of Purchasers of Sun Communities, Inc. Publicly-Traded Common Stock - SUI
assistance obtaining a Notice of Pendency and Proposed Settlement of Class Action ("Long Notice") and a copy of the Proof of Claim and Release Form ("Claim Form"), you may write to, call, or contact the Claims Administrator: Sun Communities, Inc. Securities Litigation, c/o Strategic Claims Services, P.O.
More news about: The Rosen Law Firm, P.A.
May 30, 2026, 08:00 ET How Restoration Expert Brett Swiatek of Buffalo Explains Stained Glass Restoration for HelloNation
long-term preservation.Drafts or leaks are also indicators that restoration may be overdue. When the sealing putty around the glass dries out, gaps form between the glass, lead, and frame. These openings allow water and air to enter, which can corrode metal, discolor the glass, and damage nearby wood
More news about: HelloNation
May 30, 2026, 08:00 ET GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
forward-looking statements, including those factors and numerous associated risks discussed under the section entitled "Risk Factors" in our Annual Report on Form 10-K for the period ended December 31, 2025. Moreover, we operate in a dynamic and rapidly changing environment. New risks emerge from time to time.
More news about: GRAIL, Inc.
May 29, 2026, 19:13 ET IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit
https://rosenlegal.com/submit-form/?case_id=56430 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected]
More news about: THE ROSEN LAW FIRM, P. A.
May 29, 2026, 17:48 ET Researchers From NYU Langone Health's Perlmutter Cancer Center Present Latest Findings at 2026 ASCO Annual Meeting
developed a new model that may improve how doctors predict outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC), an advanced form of prostate cancer known for its biological complexity and variable response to treatment. Investigators created a prognostic tool that outperformed
More news about: NYU Langone Health System
May 29, 2026, 17:31 ET Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.Investors:
More news about: Actinium Pharmaceuticals, Inc.
May 29, 2026, 17:30 ET Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice
to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.Investors:
More news about: Actinium Pharmaceuticals, Inc.
May 29, 2026, 17:03 ET JOHN HANCOCK PREMIUM DIVIDEND FUND NOTICE TO SHAREHOLDERS - SOURCES OF DISTRIBUTION UNDER SECTION 19(a)
Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.The Fund has declared the
More news about: John Hancock Investment Management
May 29, 2026, 17:02 ET JOHN HANCOCK PREMIUM DIVIDEND FUND NOTICE TO SHAREHOLDERS - SOURCES OF DISTRIBUTION UNDER SECTION 19(a)
Fund's investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.The Fund has declared the
More news about: John Hancock Investment Management
May 29, 2026, 17:00 ET Colorado State University Global Commencement Features Two Emmy-Award Winning Speakers
and communications. Ibarra currently serves Colorado's largest school district, Denver Public Schools, and was awarded an Emmy for his work on a short form documentary following one of the district's student mariachi bands. Education helped change the trajectory of Ibarra's life, and as a result, he has
More news about: Colorado State University Global